New York Consolidated Laws, Public Health Law - PBH § 2500-a. Test for phenylketonuria and other diseases and conditions

(b) Homozygous sickle cell disease.

(c) Hypothyroidism.

(d) Branched-chain ketonuria.

(e) Galactosemia.

(f) Homocystinuria.

(g) Critical congenital heart defects through pulse oximetry screening.

(h) With regard to any newborn infant who is identified as, or suspected of, having a hearing impairment as a result of a screening conducted pursuant to section twenty-five hundred-g of this title, a urine polymerase chain reaction (PCR) test for cytomegalovirus, unless the parent of the infant objects thereto;  provided that if the commissioner determines that another test for cytomegalovirus is diagnostically equivalent to or better than the urine polymerase chain reaction test, the commissioner may, by regulation under this section, allow or require the use of that other test.

(i) Adrenoleukodystrophy.

(j) Glucose-6-phosphate dehydrogenase deficiency using a quantitative enzymatic test or other diagnostic test in cases where:  the newborn infant presents with hemolytic anemia, hemolytic jaundice, or early-onset increasing neonatal jaundice, that is, jaundice (bilirubin level greater than fortieth percentile for age in hours) persisting beyond the day of birth through the week after birth;  the newborn infant has been admitted to the hospital for jaundice following birth;  or the biological parent of the newborn infant indicates a family, racial, or ethnic risk of glucose-6-phosphate dehydrogenase deficiency, including having significant African, Asian, Mediterranean, or Middle Eastern ancestry.

(k) Duchenne muscular dystrophy using a test validated by the Wadsworth center for laboratories and research.